Clinical Trials Logo

Opioid Overdose clinical trials

View clinical trials related to Opioid Overdose.

Filter by:

NCT ID: NCT03924505 Recruiting - Opioid Overdose Clinical Trials

Preventing Opioid Overdose Mortality in the United States

Start date: September 3, 2019
Phase: N/A
Study type: Interventional

This study aims to generate knowledge regarding the process of implementing naloxone within syringe service programs (SSPs), and to test whether external facilitation can improve implementation of naloxone within SSPs throughout the country. Together, these efforts can improve access to naloxone for people at high risk of overdose, thereby improving our nation's response to the opioid overdose epidemic.

NCT ID: NCT02662153 Completed - Opioid Overdose Clinical Trials

Incidence and Predictors of Opioid Overdose and Death Among Long-Term Users of Opioid Analgesics

Start date: May 2, 2019
Phase:
Study type: Observational

Retrospective study to assess incidence and predictors of opioid abuse overdose and death associated with opioid overdose among patients prescribed opioid products in long-term use.

NCT ID: NCT02535494 Completed - Opioid Overdose Clinical Trials

Risks and Benefits of Naloxone Prescribing

Start date: July 2014
Phase: N/A
Study type: Interventional

This investigation is one of the first large-scale, prospective attempts to obtain data on the effectiveness of naloxone distribution among opioid-abusing populations at high risk of unintentional opioid poisoning. Specifically, opioid abusers will be recruited from drug detoxification sites as well as those accessing services at needle exchange programs. All participants (N=700) will receive the standard opioid overdose education and naloxone. One third of the participants will be randomized to receive additional in-depth psychosocial education focusing on recognition and prevention of opioid overdose, and appropriate use of naloxone. Another third of the participants will receive the extensive training and be required to engage a spouse, partner, relative, or friend in this supplementary intervention. The investigators plan to randomize individuals to each group [Treatment as Usual (TAU) vs. Extensively Trained (ET) vs. Extensively Trained with a Significant Other (ETwSO)] and, through continued follow up over one year, the investigators will compare self-reported overdose reversal attempts (with and without naloxone use), naloxone-related adverse events, and changes in patterns of heroin and other drug use.

NCT ID: NCT01788306 Completed - Opioid Overdose Clinical Trials

Project OOPEN: Opioid Overdose Prevention, Education and Intervention

OOPEN
Start date: January 2013
Phase: Phase 4
Study type: Interventional

This prospective, randomized emergency department trial will study the effectiveness of an intervention that combines opioid overdose prevention, education and intervention that includes take home naloxone with brief behavioral change counseling. The study will recruit both heroin users (n=500) and pharmaceutical opioid users at elevated risk for overdose (n=500). Outcomes of interest include subsequent opioid overdoses and overdose risk behaviors. Primary Aims The primary aims are to test whether those who receive the intervention compared to standard care have: 1) Lower rates of opioid non-fatal and fatal overdose; 2) Reduce drug use, inappropriate medication use, and other overdose risk behaviors. Secondary Aims The secondary aims are to test whether those who receive the intervention compared to standard care have: 3) More appropriate health care utilization (e.g. fewer emergency department visits and admissions to inpatient care); 4) Lower total health care costs; 5) Determine the prevalence of HIV risk behaviors among heroin and pharmaceutical opioid users at risk for overdose and whether the intervention impacts these behaviors.

NCT ID: NCT01622504 Not yet recruiting - Opioid Overdose Clinical Trials

Naloxone Nasal Spray Pharmacokinetic Study

Start date: June 2012
Phase: Phase 1
Study type: Interventional

This study aims to compare the pharmacokinetics of naloxone when administered as the Mitovie nasal spray (Test Product) and as a solution for injection (Comparator Product) administered intranasally using a mucosal atomization device (MAD).